Analyst consensus rating
Kura Oncology Analyst Rating: none
Direct answer
Kura Oncology's consensus rating is none.
12 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $32.00.
Forecast evidence checked September 28, 2026.
Get free Kura Oncology email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $10.61
- Average price target
- $32.00
- High price target
- $76.00
- Low price target
- $15.00
- Low target gap
- +41.4%
- Target upside
- +201.6%
- High target gap
- +616.3%
- Target range width
- 574.9%
- Consensus rating
- none
- Analysts
- 12
- Evidence date
- September 28, 2026
- Valid through
- October 5, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Kura Oncology?
Kura Oncology has a verified none consensus. The same dataset has an average price target of $32.00.
How far are Kura Oncology's low and high targets from the recorded price?
The low target implies +41.4%, while the high target implies +616.3%.
How many analysts are included in Kura Oncology's consensus?
The verified consensus includes 12 analysts.
How is Kura Oncology's target upside or downside calculated?
The average target of $32.00 is divided by the recorded price of $10.61, then one is subtracted to produce +201.6%. This does not guarantee a future return.
When was Kura Oncology's analyst forecast verified?
The data was verified on 2026-09-28. The dataset is valid through 2026-10-05.